Conjugated To A Cytotoxic Agent, Drug, Or Other Biologically-active Substance Patents (Class 530/391.7)
-
Publication number: 20140377253Abstract: The present disclosure relates to polypeptide variants having modified Fc domains with altered affinity to Fc receptors.Type: ApplicationFiled: March 14, 2014Publication date: December 25, 2014Applicant: ABBVIE BIOTHERAPEUTICS INC.Inventors: Fiona A. HARDING, Paul R. HINTON, Mengli XIONG, Olivia Jennifer RAZO, Shiming YE
-
Publication number: 20140377287Abstract: Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity.Type: ApplicationFiled: July 1, 2014Publication date: December 25, 2014Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20140377781Abstract: Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.Type: ApplicationFiled: September 10, 2014Publication date: December 25, 2014Inventor: Kenji YOSHIDA
-
Publication number: 20140378668Abstract: A new and versatile class of cyclic diazodicarboxamides that reacts efficiently and selectively with phenols and the phenolic side chain of tyrosine through an Ene-like reaction is reported. This mild aqueous tyrosine ligation reaction works over a broad pH range and expands the repertoire of aqueous chemistries available for small molecule, peptide, and protein modification. The tyrosine ligation reactions are shown to be compatible with the labeling of native enzymes and antibodies in buffered aqueous solution. This reaction provides a novel synthetic approach to bispecific antibodies. This reaction will find broad utility in peptide and protein chemistry and in the chemistry of phenol-containing compounds.Type: ApplicationFiled: June 25, 2014Publication date: December 25, 2014Inventors: Carlos F. Barbas, III, Hitoshi Ban, Julia Gavrilyuk
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
Publication number: 20140369926Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: J. Andrew BRISTOL, Judith A. KANTOR
-
Publication number: 20140371432Abstract: The present invention provides a double-stranded RNA structure, which comprises a polymer compound covalently bonded to a double-helix oligo RNA useful for the treatment of diseases, particularly cancer, in order to enhance the delivery of the double-helix oligo RNA, and further comprises a target-specific ligand bonded thereto, a preparation method thereof, and a technique of delivering the double-helix oligo RNA in a target-specific manner using the RNA structure. A nanoparticle composed of the ligand-bonded double-helix oligo RNA structures can efficiently deliver the double-helix oligo RNA to a target, and thus can exhibit the activity of the double-helix oligo RNA even when the double-helix oligo RNA is administered at a relatively low concentration. Also, it can prevent the non-specific delivery of the double-helix oligo RNA into other organs and cells.Type: ApplicationFiled: December 14, 2012Publication date: December 18, 2014Inventors: Jeiwook Chae, Boram Han, Han-na Kim, Han Oh Park, Pyoung Oh Yoon, Sun Gi Kim, Kwang-Ju Jung, Taewoo Kwon, Jong Deok Choi, Sam Young Lee, Eun-Jung Jung
-
Publication number: 20140370036Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.Type: ApplicationFiled: August 21, 2014Publication date: December 18, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATEInventor: Leland SHAPIRO
-
Publication number: 20140371286Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.Type: ApplicationFiled: January 23, 2014Publication date: December 18, 2014Applicant: North Carolina State UniversityInventors: Han-Je Kim, Jonathan S. Lindsey
-
Publication number: 20140370016Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: July 31, 2014Publication date: December 18, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8912311Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.Type: GrantFiled: April 16, 2013Date of Patent: December 16, 2014Assignees: Københavns Universitet, Cancer Research Technology LimitedInventors: Henrik Clausen, Joy Burchell, Ulla Mandel, Anne Louise Sørensen, Mads Agervig Tarp, Joyce Taylor-Papadimitriou
-
Publication number: 20140363439Abstract: The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Applicant: GENENTECH, INC.Inventors: Eric Bourhis, Rick Carano, Andrea Cochran, Mike Costa, Venita DeAlmeida, James Ernst, Yan Gong, Rami Hannoush, Paul Polakis, Bonnee Rubinfeld, Mark Solloway, Yan Wu
-
Publication number: 20140363438Abstract: The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1? and neuregulin 1? isoforms.Type: ApplicationFiled: August 16, 2012Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Erica Jackson, Gabriele Schaefer, Yan Wu
-
Publication number: 20140364593Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.Type: ApplicationFiled: August 22, 2014Publication date: December 11, 2014Applicant: STEM CENTRX, INC.Inventors: ROBERT A. STULL, LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, DAVID LIU, MICHAEL TORGOV, HUI SHAO
-
Publication number: 20140363434Abstract: The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: January 4, 2013Publication date: December 11, 2014Applicant: COMPLIX NVInventors: Ignace Lasters, Mark Vaeck, Johan Desmet, Jürgen Debaveye, Sabrina Deroo, Stefan Loverix
-
Publication number: 20140363873Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: May 8, 2014Publication date: December 11, 2014Applicant: Genentech, Inc.Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
-
Patent number: 8906342Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: October 14, 2013Date of Patent: December 9, 2014Assignee: Abbvie Biotherapeutics Inc.Inventors: Debbie Law, Kurt Gish
-
Patent number: 8906379Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.Type: GrantFiled: January 20, 2012Date of Patent: December 9, 2014Assignee: Genzyme CorporationInventor: James Stefano
-
Patent number: 8907069Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: July 5, 2010Date of Patent: December 9, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
-
Publication number: 20140356364Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.Type: ApplicationFiled: August 15, 2012Publication date: December 4, 2014Applicant: AMPLIMMUNE, INC.Inventors: Solomon Langermann, Linda Liu, Shannon Marshall
-
Publication number: 20140356281Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: July 3, 2014Publication date: December 4, 2014Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
-
Publication number: 20140357843Abstract: The present invention relates to immunoglobulin Fc variants having an increased binding affinity for FcRn, which is characterized by including one or more amino acid modifications selected from the group consisting of 307S, 308F, 380S, 380A, 428L, 429K, 430S, 433K and 434S (this numbering is according to the EU index) in the constant region of a native immunoglobulin Fc fragment. Owing to the high binding affinity for FcRn, the immunoglobulin Fc variants according to the present invention show more prolonged in vivo half-life, and thus can be used for the preparation of a long-acting formulation of protein drugs.Type: ApplicationFiled: December 28, 2012Publication date: December 4, 2014Applicant: HANMI SCIENCE CO., LTDInventors: Euh Lim Oh, Yong Ho Huh, Sang Youn Hwang, In Young Choi, Sung Youb Jung, Se Chang Kwon
-
Publication number: 20140356375Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 22, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20140356376Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Applicant: GENENTECH, INC.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Publication number: 20140356930Abstract: This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer.Type: ApplicationFiled: June 3, 2013Publication date: December 4, 2014Inventor: Hossein A. Ghanbari
-
Patent number: 8900578Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.Type: GrantFiled: July 30, 2013Date of Patent: December 2, 2014Assignee: ZymoGenetics, Inc.Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8900589Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: July 14, 2009Date of Patent: December 2, 2014Assignee: Genetech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
-
Patent number: 8900580Abstract: The invention relates to the use of anti-IL-6 antibodies or antibody fragments containing a specific epitopic specificity to treat conditions involving elevated Il-6. In some embodiments the anti-IL-6 antibodies contain specific CDRs.Type: GrantFiled: November 24, 2009Date of Patent: December 2, 2014Assignee: AlderBio Holdings LLCInventors: Leon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, John Latham, Brian Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
-
Publication number: 20140351961Abstract: Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.Type: ApplicationFiled: August 30, 2012Publication date: November 27, 2014Inventor: Alexzander A. Asea
-
Publication number: 20140350228Abstract: The invention provides processes for manufacturing cell-binding agent-cytotoxic agent conjugates of improved stability in the presence of exogenous NHS. In some embodiments, the inventive process comprises the addition of a molar ratio of exogenous NHS with respect to the amount of NHS generated during the modification reaction as a result of hydrolysis/aminolysis of the bifunctional linker.Type: ApplicationFiled: December 13, 2012Publication date: November 27, 2014Applicant: ImmunoGen, Inc.Inventors: Fang Liu, Godfrey W. Amphlett, Deborah H. Meshulam
-
Publication number: 20140349929Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: March 28, 2014Publication date: November 27, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
-
Publication number: 20140349944Abstract: The present disclosure provides isolated integrin ?L polypeptides, such as ?7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation.Type: ApplicationFiled: May 23, 2014Publication date: November 27, 2014Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Zihai LI, Feng HONG
-
Publication number: 20140348836Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.Type: ApplicationFiled: September 5, 2012Publication date: November 27, 2014Applicant: Alligator Bioscience ABInventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
-
Publication number: 20140348784Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ? (TNF?) or Tissue Factor protein (which may be truncated).Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Applicant: PHILOGEN S.P.A.Inventors: Luciano ZARDI, Dario NERI, Barbara CARNEMOLLA, Fredrik NILSSON, Lorenzo TARLI, Laura BORSI, Cornelia HALIN
-
Patent number: 8895007Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: December 7, 2011Date of Patent: November 25, 2014Assignee: Affitech Research ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Publication number: 20140341809Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.Type: ApplicationFiled: May 16, 2014Publication date: November 20, 2014Applicants: University of Massachusetts, University of Notre DameInventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
-
Publication number: 20140341904Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140341905Abstract: The invention provides compositions comprising SPARC binding ScFc and its use.Type: ApplicationFiled: August 5, 2014Publication date: November 20, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Vuong Trieu
-
Patent number: 8889140Abstract: The present invention provides compositions and methods for targeting an extracellular matrix derived (EMD) peptide predominantly to an injured tissue, as opposed to an uninjured tissue in vivo. The targeted EMD peptide facilitates the repair and/or regeneration of the injured tissue by providing a surface for cells to attach and grow, thereby facilitating the repair and/or regeneration of the injured tissue.Type: GrantFiled: May 30, 2008Date of Patent: November 18, 2014Assignees: TransTarget, Inc., The Regents of the University of CaliforniaInventors: Randall J. Lee, Shirley Mihardja, Manley Huang, James W. Larrick
-
Publication number: 20140335568Abstract: The present disclosure relates to a nucleic acid assembly (NAA), comprising sensor domain and handle domain; an assembly interfaceable motif (AIM) sequence optionally along with intracellular targeting motif (ITM) sequence; and an AIM-NAA complex. It also relates to a vector comprising assembly interfaceable motif sequence optionally along with intracellular targeting motif sequence and a cell comprising the vector. Further, the instant disclosure also provides a method to obtain the nucleic acid assembly, method of intracellular targeting and kit thereof.Type: ApplicationFiled: October 11, 2012Publication date: November 13, 2014Applicant: NATIONAL CENTRE FOR BIOLOGICAL SCIENCESInventors: Yamuna Krishnan, Souvik Modi
-
Publication number: 20140335108Abstract: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Inventors: Kenneth Walsh, Ling Zeng
-
Publication number: 20140335107Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: March 19, 2014Publication date: November 13, 2014Applicant: GENENTECH, INC.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson
-
Publication number: 20140335103Abstract: The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.Type: ApplicationFiled: April 3, 2014Publication date: November 13, 2014Applicant: Cellerant Therapeutics, Inc.Inventor: Holger Karsunky
-
Publication number: 20140335014Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: April 8, 2014Publication date: November 13, 2014Applicant: AbbVie, Inc.Inventors: Tariq Ghayur, Peter C. Isakson, Lisa M. Olson, Chengbin Wu, Margaret Hugunin, Rajesh V. Kamath, Carolyn A. Cuff, Hamish Allen
-
Publication number: 20140336110Abstract: Disclosed herein are peptides which exhibit hepcidin activity and methods of making and using thereof.Type: ApplicationFiled: December 6, 2012Publication date: November 13, 2014Applicant: The Regents of the University of CaliforniaInventors: Tomas Ganz, Elizabeta Nemeth, Piotr P. Ruchala
-
Publication number: 20140328758Abstract: The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: NICOLAE GHINEA, AURELIAN RADU
-
Publication number: 20140328849Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.Type: ApplicationFiled: March 14, 2014Publication date: November 6, 2014Applicant: GENENTECH, INC.Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
-
Publication number: 20140328830Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.Type: ApplicationFiled: December 24, 2013Publication date: November 6, 2014Applicant: ONCOSYNERGY, INC.Inventor: W. Shawn Carbonell